Traws Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. The company is headquartered in Newtown, Pennsylvania and currently employs 7 full-time employees. The company went IPO on 2013-07-25. The company integrates antiviral drug development, medical intelligence and regulatory strategy in the treatment of viral diseases. The Cadvancing novel investigational oral small-molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Its four clinical programs consist of Tivoxavir marboxil, Ratutrelvir (TRX0), Narazaciclib, and Rigosertib. Tivoxavir marboxil is a small-molecule cap-dependent endonuclease inhibitor. Ratutrelvir (TRX01) is an inhibitor of the main protease (also known as 3CL protease) of the SARS-CoV-2 virus. arazaciclib is its oral CDK4-plus inhibitor intended initially to treat breast cancers, endometrial and other cancers. Rigosertib is its second asset in oncology.
P/E (price / listing EPS) Forward revenue growth (NTM) 
